Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Prostate Cancer

Free Subscription 23.12.2024 1 AJR Am J Roentgenol 3 BJU Int 1 BMC Cancer 2 BMC Urol 2 Br J Cancer 3 Br J Radiol 1 Cancer Lett 1 Cancer Res 2 Clin Imaging 2 Eur Radiol 7 Eur Urol 1 Int J Cancer 3 Int J Radiat Oncol Biol Phys 4 Int J Urol 2 J Clin Oncol 2 J Urol 2 N Engl J Med 2 Nat Rev Urol 2 Oncogene 1 Oncol Rep 1 PLoS Genet 4 PLoS One 4 Prostate 6 Urology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. LEWIS S, Rastinehad AR
   Beyond the AJR: Prostate Cancer Screening-Safe Omission of Biopsy in Patients With Negative MRI and the Need for High-Quality Imaging Standards.
   AJR Am J Roentgenol. 2024 Dec 11. doi: 10.2214/AJR.24.32431.
   PubMed        
   
   

   
   BJU Int

2. OKHAWERE KE, Razdan S, Beksac AT, Saini I, et al
   Novel bioabsorbable, low-dose rate brachytherapy device (CivaSheet((R))) with radical prostatectomy and adjuvant external beam radiation for the management of prostate cancer.
   BJU Int. 2024 Dec 9. doi: 10.1111/bju.16617.
   PubMed         Abstract available
   
   
3. GELIKMAN DG, Azar WS, Yilmaz EC, Lin Y, et al
   A Prostate Imaging-Reporting and Data System version 2.1-based predictive model for clinically significant prostate cancer diagnosis.
   BJU Int. 2024 Dec 9. doi: 10.1111/bju.16616.
   PubMed         Abstract available
   
   
4. CHIU PK, Liu AQ, Lau SY, Teoh JY, et al
   A 2-year prospective evaluation of the Prostate Health Index in guiding biopsy decisions in a large cohort.
   BJU Int. 2025;135:71-77.
   PubMed         Abstract available
   
   

   
   BMC Cancer

5. KIRLI BOLUKBAS M, Figen M, Kocak Uzel E
   Cancer awareness across borders: a comparative study of internet search trends for breast and prostate cancer in Europe and Turkey.
   BMC Cancer. 2024;24:1563.
   PubMed         Abstract available
   
   

   
   BMC Urol

6. YUAN S, Bi X, Shayiti F, Niu Y, et al
   Relationship between circulating miRNA-222-3p and miRNA-136-5p and the efficacy of docetaxel chemotherapy in metastatic castration-resistant prostate cancer patients.
   BMC Urol. 2024;24:275.
   PubMed         Abstract available
   
   
7. CHEN L, Shuang H, Qingjian W, Jingzhen Z, et al
   Bone health management in endocrine-treated patients with prostate cancer: a summary of evidence.
   BMC Urol. 2024;24:271.
   PubMed         Abstract available
   
   

   
   Br J Cancer

8. LUO L, Wang R, Bai L, Shang J, et al
   The accuracy of fluorine 18-labelled prostate-specific membrane antigen PET/CT and MRI for diagnosis of prostate cancer in PSA grey zone.
   Br J Cancer. 2024 Dec 19. doi: 10.1038/s41416-024-02934.
   PubMed         Abstract available
   
   
9. CHEN M, Zhou S, He X, Wen H, et al
   Identification of diagnostic biomarkers in prostate cancer-related fatigue by construction of predictive models and experimental validation.
   Br J Cancer. 2024 Dec 15. doi: 10.1038/s41416-024-02922.
   PubMed         Abstract available
   
   

   
   Br J Radiol

10. GUTIERREZ-VALENCIA E, Navarro-Domenech I, Zhou K, Barcelona M, et al
    Partial or Focal Brachytherapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
    Br J Radiol. 2024 Dec 19:tqae254. doi: 10.1093.
    PubMed         Abstract available
    
    
11. 
    Correction: Proton therapy for prostate cancer: current state and future perspectives.
    Br J Radiol. 2024 Dec 11:tqae245. doi: 10.1093.
    PubMed        
    
    
12. ZENG HJ, Yang L, Yao J
    Multiparameter magnetic resonance imaging features of prostatic malakoplakia.
    Br J Radiol. 2024 Oct 8:tqae205. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Cancer Lett

13. STEINER L, Eldh M, Offens A, Veerman RE, et al
    Protein profile in urinary extracellular vesicles is a marker of malignancy and correlates with muscle invasiveness in urinary bladder cancer.
    Cancer Lett. 2024;609:217352.
    PubMed         Abstract available
    
    

    
    Cancer Res

14. SIPOLA J, Munzur AD, Kwan EM, Seo CCY, et al
    Plasma cell-free DNA chromatin immunoprecipitation profiling depicts phenotypic and clinical heterogeneity in advanced prostate cancer.
    Cancer Res. 2024 Dec 9. doi: 10.1158/0008-5472.CAN-24-2052.
    PubMed         Abstract available
    
    

    
    Clin Imaging

15. ESENGUR OT, Yilmaz EC, Ozyoruk KB, Chen A, et al
    Multimodal approach to optimize biopsy decision-making for PI-RADS 3 lesions on multiparametric MRI.
    Clin Imaging. 2025;117:110363.
    PubMed         Abstract available
    
    
16. COCHRAN RL, Milshteyn E, Ghosh S, Nakrour N, et al
    Minimizing prostate diffusion weighted MRI examination time through deep learning reconstruction.
    Clin Imaging. 2025;117:110341.
    PubMed         Abstract available
    
    

    
    Eur Radiol

17. DEBS N, Routier A, Bone A, Rohe MM, et al
    Evaluation of a deep learning prostate cancer detection system on biparametric MRI against radiological reading.
    Eur Radiol. 2024 Dec 19. doi: 10.1007/s00330-024-11287.
    PubMed         Abstract available
    
    
18. BAUCKNEHT M, Laudicella R, Lanfranchi F, Ciccarese C, et al
    PSMA PET/CT in staging recurrent prostate cancer: a viewfinder, not a compass.
    Eur Radiol. 2024 Dec 18. doi: 10.1007/s00330-024-11297.
    PubMed        
    
    

    
    Eur Urol

19. STRANNE J, Henry A, Oprea-Lager DE
    Use of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Nodal Staging in Prostate Cancer and Tailoring of Treatment: A Continuing Conundrum.
    Eur Urol. 2024 Dec 18:S0302-2838(24)02745-3. doi: 10.1016/j.eururo.2024.
    PubMed         Abstract available
    
    
20. TISSEVERASINGHE S, Tolba M, Saad F, Fizazi K, et al
    Optimal Treatment Strategies for Hormone-sensitive Metastatic Prostate Cancer: Does Local Radiotherapy Play a Role in High-volume Disease?
    Eur Urol. 2024 Dec 17:S0302-2838(24)02748-9. doi: 10.1016/j.eururo.2024.
    PubMed         Abstract available
    
    
21. DIAS AB, Moore CM, Renard-Penna R, Giganti F, et al
    Biparametric Versus Multiparametric Magnetic Resonance Imaging in Prostate Cancer: A Choice or a Fine Balance?
    Eur Urol. 2024 Dec 16:S0302-2838(24)02740-4. doi: 10.1016/j.eururo.2024.
    PubMed        
    
    
22. EL-TAJI O, Clarke NW
    Balancing Efficacy and Cardiotoxicity in Prostate Cancer Therapy: A Call for Precision in Treatment Strategies.
    Eur Urol. 2025;87:27-28.
    PubMed        
    
    
23. DAVIS JW
    Multiparametric Magnetic Resonance Imaging with Targeted-only Biopsy-A New Standard for Guidelines on Prostate Cancer Detection?
    Eur Urol. 2024 Dec 11:S0302-2838(24)02717-9. doi: 10.1016/j.eururo.2024.
    PubMed        
    
    
24. SCHAFER EJ, Laversanne M, Sung H, Soerjomataram I, et al
    Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An Update.
    Eur Urol. 2024 Dec 5:S0302-2838(24)02707-6. doi: 10.1016/j.eururo.2024.
    PubMed         Abstract available
    
    
25. ONG WL, Romero T, Roy S, Nikitas J, et al
    Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): A Pooled Analysis of Five Randomized Trials from the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium.
    Eur Urol. 2025;87:49-57.
    PubMed         Abstract available
    
    

    
    Int J Cancer

26. MCGRATH CB, Shreves AH, Shanahan MR, Guard HE, et al
    Etiology of prostate cancer with the TMPRSS2:ERG fusion: A systematic review of risk factors.
    Int J Cancer. 2024 Dec 11. doi: 10.1002/ijc.35279.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

27. CHOO R, Corbin K, Merrell K, Stish B, et al
    Five-year outcomes of moderately hypofractionated proton therapy incorporating elective pelvic nodal irradiation for high-risk prostate cancer.
    Int J Radiat Oncol Biol Phys. 2024 Dec 11:S0360-3016(24)03722.
    PubMed         Abstract available
    
    
28. ZHANG P, Happersett L, Burleson S, Oh JH, et al
    Reduction of Postradiation Therapy Urinary Toxicity Via Intrafractional Megavoltage-Kilovoltage Prostate Location Monitoring.
    Int J Radiat Oncol Biol Phys. 2025;121:261-268.
    PubMed         Abstract available
    
    
29. RAJENDRAN P, Chen Y, Qiu L, Niedermayr T, et al
    Autodelineation of Treatment Target Volume for Radiation Therapy Using Large Language Model-Aided Multimodal Learning.
    Int J Radiat Oncol Biol Phys. 2025;121:230-240.
    PubMed         Abstract available
    
    

    
    Int J Urol

30. YE DW, Uemura H, Chung BH, Suzuki H, et al
    Prostate-specific antigen kinetics in Asian patients with metastatic castration-sensitive prostate cancer treated with apalutamide in the TITAN trial: A post hoc analysis.
    Int J Urol. 2024 Dec 9. doi: 10.1111/iju.15615.
    PubMed         Abstract available
    
    
31. SUZUKI H, Akamatsu S, Shiota M, Kakiuchi H, et al
    Triplet therapy for metastatic castration-sensitive prostate cancer: Rationale and clinical evidence.
    Int J Urol. 2024 Dec 9. doi: 10.1111/iju.15647.
    PubMed         Abstract available
    
    
32. KUMAR V, Jena D, Zahiruddin QS, Roopashree R, et al
    Prostate cancer burden in South Asia: A systematic analysis of global burden of disease data (1990-2021).
    Int J Urol. 2024 Dec 13. doi: 10.1111/iju.15641.
    PubMed         Abstract available
    
    
33. CHEN W, Yoshida S, Miura N, Fukuda S, et al
    Efficacy of docetaxel addition to next-generation androgen receptor-axis-targeted therapies and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: A tumor volume-specific analysis.
    Int J Urol. 2024 Dec 20. doi: 10.1111/iju.15657.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

34. ARONSON WJ, Grogan T, Liang P, Jardack P, et al
    High Omega-3, Low Omega-6 Diet With Fish Oil for Men With Prostate Cancer on Active Surveillance: The CAPFISH-3 Randomized Clinical Trial.
    J Clin Oncol. 2024 Dec 13:JCO2400608. doi: 10.1200/JCO.24.00608.
    PubMed         Abstract available
    
    
35. DIZMAN N, Necchi A
    Promises and Challenges of Dietary Intervention in Patients With Prostate Cancer: Lessons Learned From the CAPFISH-3 Trial.
    J Clin Oncol. 2024 Dec 13:JCO2402444. doi: 10.1200/JCO-24-02444.
    PubMed        
    
    

    
    J Urol

36. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2025;213:138-140.
    PubMed        
    
    
37. JONES JM, Matthew A, Tanguay S, Higano CS, et al
    A Tailored Electronic Survivorship Care Plan for Prostate Cancer Survivors: A Multicenter Randomized Controlled Trial.
    J Urol. 2024 Dec 20:101097JU0000000000004359. doi: 10.1097/JU.0000000000004359.
    PubMed         Abstract available
    
    

    
    N Engl J Med

38. TILKI D, Chen MH, D'Amico AV
    Four Years of Screening for Prostate Cancer with PSA and MRI.
    N Engl J Med. 2024;391:2273-2274.
    PubMed        
    
    
39. HUGOSSON J, Godtman RA, Stranne J
    Four Years of Screening for Prostate Cancer with PSA and MRI. Reply.
    N Engl J Med. 2024;391:2274.
    PubMed        
    
    

    
    Nat Rev Urol

40. LLOYD L
    PEACEing together prostate cancer therapy.
    Nat Rev Urol. 2024 Dec 6. doi: 10.1038/s41585-024-00982.
    PubMed        
    
    
41. MASONE MC
    Personalized 3D models for prostate cancer surgery.
    Nat Rev Urol. 2024 Dec 11. doi: 10.1038/s41585-024-00986.
    PubMed        
    
    

    
    Oncogene

42. DUTTA S, Khedmatgozar H, Patel GK, Latour D, et al
    A TBX2-driven signaling switch from androgen receptor to glucocorticoid receptor confers therapeutic resistance in prostate cancer.
    Oncogene. 2024 Dec 20. doi: 10.1038/s41388-024-03252.
    PubMed         Abstract available
    
    
43. WOYTASH JA, Kumar R, Chaudhary AK, Donnelly C, et al
    Mitochondrial unfolded protein response-dependent beta-catenin signaling promotes neuroendocrine prostate cancer.
    Oncogene. 2024 Dec 17. doi: 10.1038/s41388-024-03261.
    PubMed         Abstract available
    
    

    
    Oncol Rep

44. YANG C, Wang L, Gong C, Lv D, et al
    Antibody?drug conjugates in prostate cancer: Emerging strategies to enhance therapeutic index and current clinical landscape (Review).
    Oncol Rep. 2025;53:21.
    PubMed         Abstract available
    
    

    
    PLoS Genet

45. RIVERA IS, French JD, Bitar M, Sivakumaran H, et al
    GWAS and 3D chromatin mapping identifies multicancer risk genes associated with hormone-dependent cancers.
    PLoS Genet. 2024;20:e1011490.
    PubMed         Abstract available
    
    

    
    PLoS One

46. MAJUMDAR K, Silva R, Perry AS, Watson RW, et al
    A novel family of beta mixture models for the differential analysis of DNA methylation data: An application to prostate cancer.
    PLoS One. 2024;19:e0314014.
    PubMed         Abstract available
    
    
47. ZHANG T, Li W, Wei H, Huang Z, et al
    Prognostic value of baseline alkaline phosphatase of 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.
    PLoS One. 2024;19:e0307826.
    PubMed         Abstract available
    
    
48. AZAM H, Veale C, Zitzmann K, Marcone S, et al
    Identification of druggable targets from the interactome of the Androgen Receptor and Serum Response Factor pathways in prostate cancer.
    PLoS One. 2024;19:e0309491.
    PubMed         Abstract available
    
    
49. WEINSTEIN SJ, Parisi D, Mondul AM, Layne TM, et al
    Vitamin D binding protein genetic isoforms, serum vitamin D, and cancer risk in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    PLoS One. 2024;19:e0315252.
    PubMed         Abstract available
    
    

    
    Prostate

50. YORIOKA MAW, Murta CB, Leite KRM, Cardili L, et al
    ERG and PTEN Role on Active Surveillance for Low-Risk Prostate Cancer in the Multiparametric MRI Era.
    Prostate. 2024 Dec 9:e24835. doi: 10.1002/pros.24835.
    PubMed         Abstract available
    
    
51. CHIARELLI G, Davis M, Stephens A, Finati M, et al
    Racial Disparities in Future Development of Lethal Prostate Cancer Based on Midlife Baseline Prostate-Specific Antigen.
    Prostate. 2024 Dec 9:e24834. doi: 10.1002/pros.24834.
    PubMed         Abstract available
    
    
52. DIAMAND R, Bernard PL, Mjaess G, Benijts J, et al
    Retzius-sparing versus standard robot-assisted laparoscopic prostatectomy: A two-year patient-reported and oncological assessment.
    Prostate. 2025;85:115-122.
    PubMed         Abstract available
    
    
53. CHAI H, Miyasaka Y, Hagiwara Y, Souda H, et al
    Investigation of pelvic floor influence on prostate displacement in image-guided radiotherapy.
    Prostate. 2025;85:123-129.
    PubMed         Abstract available
    
    

    
    Urology

54. LEAPMAN MS
    Market Forces in Prostate Cancer Care.
    Urology. 2024 Dec 16:S0090-4295(24)01140-3. doi: 10.1016/j.urology.2024.
    PubMed        
    
    
55. CHECCUCCI E, Bauckneht M, Gandaglia G, Porpiglia F, et al
    REPLY TO "PSMA PET-targeted Biopsy for Prostate Cancer Diagnosis: Initial Experience from a Multicenter Cohort".
    Urology. 2024 Dec 13:S0090-4295(24)01138-5. doi: 10.1016/j.urology.2024.
    PubMed        
    
    
56. BACA AL, Chung C, Kanmaniraja D, Duong TQ, et al
    A Call for the Inclusion and Reporting of Race and Ethnicity Demographics in Artificial Intelligence Research for Prostate Cancer Detection on Magnetic Resonance Imaging.
    Urology. 2024 Dec 4:S0090-4295(24)01097-5. doi: 10.1016/j.urology.2024.
    PubMed        
    
    
57. CHAVARRIAGA J, Penn LZ, Khurram N, Lajkosz K, et al
    Statin Concentration in Prostatic Tissue is Subtype- and Dose-dependent.
    Urology. 2024;194:172-179.
    PubMed         Abstract available
    
    
58. QIAN Z, Chen YJ, Moman P, Labban M, et al
    Identifying Barriers to Timely Follow-up After Elevated PSA Screening: A Retrospective Analysis of a Large Healthcare System.
    Urology. 2024;194:165-171.
    PubMed         Abstract available
    
    
59. FLORES JM, Thorogood S, Jenkins LC, Miyagi H, et al
    Does Diabetes Have a Negative Impact on Erectile Function Recovery After Radical Prostatectomy?
    Urology. 2024;194:327-332.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.